DLHL
SRNE

Donald L. Hagan LLC’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Donald L. Hagan LLC’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-169,514
Closed -$150K – 123
2022
Q4 		$150K Buy
169,514
+20,037
+13% +$26.6K 0.09% 85
2022
Q3 		$235K Buy
149,477
+60,739
+68% +$138K 0.17% 82
2022
Q2 		$178K Buy
88,738
+1,804
+2% +$3.12K 0.11% 91
2022
Q1 		$203K Buy
86,934
+13,350
+18% +$41.6K 0.11% 92
2021
Q4 		$342K Buy
73,584
+30,655
+71% +$190K 0.18% 88
2021
Q3 		$328K Buy
42,929
+2,871
+7% +$24.3K 0.19% 85
2021
Q2 		$388K Buy
40,058
+3,935
+11% +$31.3K 0.23% 79
2021
Q1 		$299K Buy
36,123
+11,697
+48% +$124K 0.2% 81
2020
Q4 		$167K Buy
24,426
+8,724
+56% +$70.1K 0.12% 83
2020
Q3 		$175K Buy
15,702
+3,600
+30% +$32.9K 0.14% 78
2020
Q2 		$76K Sell
12,102
-13,900
-53% -$53.2K 0.07% 81
2020
Q1 		$67K Buy
26,002
+4,902
+23% +$14.1K 0.06% 79
2019
Q4 		$89K Buy
+21,100
New +$50.3K 0.08% 86

Other funds holding SRNE

PP
Paloma Partners Greenwich, Connecticut $1.36B AUM 249.29% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
OFA
Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return
CGA
Crescent Grove Advisors Lake Forest, Illinois $1.2B AUM 23.08% 1-Year Est. Return
LCM
Lattice Capital Management Kirkland, Washington $49.5M AUM 28.58% 1-Year Est. Return
STB
S&T Bank Indiana, Pennsylvania $333M AUM 106.39% 1-Year Est. Return
GA
GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return
HFRG
Houlihan Financial Resource Group Ashburn, Virginia $281M AUM 17.68% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
GBWM
Granite Bay Wealth Management Portsmouth, New Hampshire $1.09B AUM 22.93% 1-Year Est. Return

Donald L. Hagan LLC's SRNE Position: Q1 2023 in Review

Donald L. Hagan LLC sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2023, closing a stake of 169,514 shares — an estimated $150K sold.

Donald L. Hagan LLC first reported a position in SRNE in Q4 2019 and held it in 13 quarters. The position peaked at $388K in Q2 2021. 34 funds tracked by Wall St. Rank hold SRNE as of Q1 2023.

  • Donald L. Hagan LLC reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
  • Donald L. Hagan LLC sold 169,514 Sorrento Therapeutics, Inc. shares in Q1 2023, an estimated $150K.
  • Donald L. Hagan LLC first reported a position in Sorrento Therapeutics, Inc. in Q4 2019 and held it in 13 quarters.
  • Donald L. Hagan LLC's Sorrento Therapeutics, Inc. position peaked at $388K in Q2 2021.
  • 34 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2023.

Based on Donald L. Hagan LLC's 13F filing for Q1 2023, filed 18 Apr 2023.